Observational studyJNMA; journal of the Nepal Medical Association2025
Immunohistochemical Expression of P16 in Cervical Lesions: An Observational Study.
Observational study in JNMA; journal of the Nepal Medical Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cervical cancer is the leading cancer and the predominant cause of cancer-associated deaths among women worldwide. Human papillomavirus infection is the foremost cause of cervical cancer. P16 tumor suppressor protein is overexpressed in high-risk HPV infected cells. This has led to the development of P16 as a reliable predictive biomarker to identify women with cervical dysplasia who are at risk of progressing to high-grade cervical intraepithelial neoplasia and invasive cancer. The study aimed to determine the expression pattern of P16 in lesions of the cervix. Methods: This observational study was conducted at Paropakar Maternity and Women's Hospital, Nepal, from June 2025 to August 2025. All patients who visited the Gynecology outpatient department for abnormal cervical screening were included in the study. An immunohistochemistry test for P16 was performed in histologically confirmed pre-invasive and invasive lesions. Results: Of 88 cervical biopsies, 34 (38.63%) lesions were preinvasive, and 20 (22.72%) lesions were invasive. P16 immunohistochemistry was performed in 52 (59.09%) histologically confirmed dysplastic and invasive cervical lesions. Among 52 dysplastic lesions, 37 (71.15%) cases were P16-positive. Out of 37 P16-positive cases, 17 (45.95%) were preinvasive and 20 (54.05%) were invasive lesions. In pre-invasive group, 1 (10 %) were CIN1 lesion, 2 (28.57%) CIN II lesions, and 14 (93.33%) CIN III lesions were P16 positive, and among 20 invasive lesions, 20 (100%) were P16 positive. Conclusions: P16 expression was found to increase with the severity of cervical dysplasia and was positive in all invasive cervical cancer cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.